PMID- 34967270
OWN - NLM
STAT- MEDLINE
DCOM- 20220223
LR  - 20220223
IS  - 1521-0464 (Electronic)
IS  - 1071-7544 (Print)
IS  - 1071-7544 (Linking)
VI  - 29
IP  - 1
DP  - 2022 Dec
TI  - A pH-responsive complex based on supramolecular organic framework for 
      drug-resistant breast cancer therapy.
PG  - 128-137
LID - 10.1080/10717544.2021.2021325 [doi]
AB  - Chemotherapy is one of the main ways to treat breast cancer clinically. However, 
      the multidrug resistance to anti-tumor drugs limits their clinical use. To 
      overcome these drawbacks, development of drug delivery systems (DDSs) has 
      attracted more and more attention in cancer therapy. At present, the preparation 
      and purification process are complicated for many reported DDSs, while clinic 
      calls for new DDSs that are more convenient for preparation. Here, a new 
      pH-responsive supramolecular organic framework drug delivery complex loading 
      doxorubicin (DOX) is fabricated. Anti-tumor activity of the system in vitro was 
      investigated by cell cytotoxicity, uptake assay, and cell apoptosis analysis. The 
      anti-tumor activity in vivo was investigated by inspecting nude mice body weight, 
      tumor volume, and weight, also a preliminary mechanism probe was conducted by HE 
      and TUNEL staining. The DOX@SOF displayed high stability, good biocompatibility, 
      and pH regulated drug release. At acid condition, the hydrazone bonds would be 
      broken, which result in the dissociation of SOF, and then the drugs would be 
      released from the system. Furthermore, DOX@SOF enhanced cellular internalization. 
      Both in vitro and in vivo experiments reflected that DOX@SOF could enhance the 
      anti-tumor activity of DOX for the MCF-7/ADR tumor cells and tumors. This study 
      provides a highly efficient strategy to prepare stimulus-responsive 
      supramolecular drug delivery complex for treatment of drug-resistant cancer, the 
      results presented inspiring scientific interests in exploring new drug delivery 
      strategy and reversing multi-drug resistance for clinical chemotherapy.
FAU - Zhang, Yun-Chang
AU  - Zhang YC
AD  - School of Pharmacy, Naval Medical University, Shanghai, China.
FAU - Zeng, Pei-Yu
AU  - Zeng PY
AD  - School of Pharmacy, Naval Medical University, Shanghai, China.
FAU - Ma, Zhi-Qiang
AU  - Ma ZQ
AD  - School of Pharmacy, Naval Medical University, Shanghai, China.
FAU - Xu, Zi-Yue
AU  - Xu ZY
AD  - Department of Chemistry, Shanghai Key Laboratory of Molecular Catalysis and 
      Innovative Materials, Fudan University, Shanghai, China.
FAU - Wang, Ze-Kun
AU  - Wang ZK
AD  - Department of Chemistry, Shanghai Key Laboratory of Molecular Catalysis and 
      Innovative Materials, Fudan University, Shanghai, China.
FAU - Guo, Beibei
AU  - Guo B
AD  - School of Pharmacy, Naval Medical University, Shanghai, China.
FAU - Yang, Feng
AU  - Yang F
AD  - School of Pharmacy, Naval Medical University, Shanghai, China.
FAU - Li, Zhan-Ting
AU  - Li ZT
AD  - Department of Chemistry, Shanghai Key Laboratory of Molecular Catalysis and 
      Innovative Materials, Fudan University, Shanghai, China.
LA  - eng
PT  - Journal Article
PL  - England
TA  - Drug Deliv
JT  - Drug delivery
JID - 9417471
RN  - 0 (Drug Carriers)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Animals
MH  - Apoptosis/drug effects
MH  - Breast Neoplasms
MH  - Cell Line, Tumor
MH  - Cell Survival/drug effects
MH  - Chemistry, Pharmaceutical
MH  - Doxorubicin/administration & dosage
MH  - Drug Carriers/*chemistry
MH  - Drug Liberation
MH  - Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Hydrogen-Ion Concentration
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Mice, Nude
MH  - Random Allocation
MH  - Surface Properties
MH  - Xenograft Model Antitumor Assays
PMC - PMC8725931
OTO - NOTNLM
OT  - Supramolecular organic framework
OT  - breast cancer
OT  - doxorubicin
OT  - drug delivery system
OT  - drug resistance
COIS- No potential conflict of interest was reported by the authors.
EDAT- 2021/12/31 06:00
MHDA- 2022/02/24 06:00
PMCR- 2021/12/30
CRDT- 2021/12/30 08:39
PHST- 2021/12/30 08:39 [entrez]
PHST- 2021/12/31 06:00 [pubmed]
PHST- 2022/02/24 06:00 [medline]
PHST- 2021/12/30 00:00 [pmc-release]
AID - 2021325 [pii]
AID - 10.1080/10717544.2021.2021325 [doi]
PST - ppublish
SO  - Drug Deliv. 2022 Dec;29(1):128-137. doi: 10.1080/10717544.2021.2021325.